References
- D. H. Gutmann, R. E. Ferner, R. H. Listernick, B. R. Korf, P. L. Wolters and K. J. Johnson, Neurofibromatosis type 1, Nat. Rev. Dis. Primer 3 (2017) Article ID 17004; https://doi.org/10.1038/nrdp.2017.4
- A. S. Michaels, Neurofibromatosis: Causes, Tests and Treatment Options (2nd ed.), CreateSpace Independent Publishing Platform, Scotts Valley (CA, USA) 2014.
- I. Solares, D. Viñal, M. Morales-Conejo, N. Rodriguez-Salas and J. Feliu, Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: A comprehensive review, ESMO Open 6(4) (2021) Article ID 100223 (10 pages); https://doi.org/10.1016/j.esmoop.2021.100223
- R. Roskoski, Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update, Pharmacol. Res. 165 (2021) Article ID 105463; https://doi.org/10.1016/j.phrs.2021.105463
- D. Casey, S. Demko, A. Sinha, P. S. Mishra-Kalyani, Y.-li Shen, S. Khasar, M. A. Goheer, W. S. Helms, L. Pan, Y. Xu, J. Fan, R. Leong, J. Liu, Y. Yang, K. Windsor, M. Ou, O. Stephens, B. Oh, G. H. Reaman, A. Nair, S. S. Shord, V. Bhatnagar, S. R. Daniels, S. Sickafuse, K. B. Goldberg, M. R. Theoret, R. Pazdur and H. Sing, FDA approval summary: Selumetinib for plexiform neurofibroma, Clin. Cancer Res. 27(15) (2021) 4142–4146; https://doi.org/10.1158/1078-0432.CCR-20-5032
- U.S. Food & Drug Administration, FDA Approves Selumetinib for Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas, US-FDA, Silver Spring (MD, USA), April 13, 2020; https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas; last access date September 22, 2024.
- S. V. Holt, A. Logié, R. Odedra, A. Heier, S. P. Heaton, D. Alferez, B. R. Davies, R. W. Wilkinson and P. D. Smith, The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models, Br. J. Cancer 106 (2012) 858–866; https://doi.org/10.1038/bjc.2012.8
- C. Li, Z. Chen, H. Yang, F. Luo, L. Chen, H. Cai, Y. Li, G. You, D. Long, S. Li, Q. Zhang and L. Rao, Selumetinib, an oral anti-neoplastic drug, may attenuate cardiac hypertrophy via targeting the ERK pathway, PloS One 11 (2016) e-0159079; https://doi.org/10.1371/journal.pone.0159079
- FDA – Center for Drug Evaluation and Research, NDA Multi-disciplinary Review and Evaluation NDA 213756 Koselugo (selumetinib), Version July 24, 2019, US FDA-CDER, Silver Spring (MD, USA), February 2020; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213756Orig1s000MultidisciplineR.pdf; last access date August 3, 2024.
- K. K. Saindane, H. Talapadatur, V. K. Munipalli, R. M. Singh, B. Fegade and V. Bhaskar, Stability indicating RP-HPLC method for the estimation of selumetinib in capsule dosage form, Int. J. Pharm. Sci. Rev. Res. 74 (2022) 166–174; https://doi.org/10.47583/ijpsrr.2022.v74i02.026
- P. Severin, C. Bailey, M. Chen, A. Fisher and V. Holmes, Determination of selumetinib, N-desmethyl selumetinib and selumetinib amide in human biological samples by LC-MS/MS, Bioanalysis 8 (2016) 1919–1936; https://doi.org/10.4155/bio-2016-0082
- J. Li, Z. Zhang, M. Yan, S. Yang, Y. Song and J. Dong, Determination of selumetinib in rat plasma by UPLC-MS/MS and application to a pharmacokinetic study, Lat. Am. J. Pharm. 39 (2020) 237–342.
- R. R. Voggu, T. S. Brus, C. T. Barksdale, P. Severin, P. Hansen, R. Chudnovskiy, E. Thomas and C. Bailey, Novel LC-MS/MS method for the determination of selumetinib (AZD6244) in whole blood collected with volumetric absorptive microsampling, Bioanalysis 12 (2020) 883–892; https://doi.org/10.4155/bio-2020-0062
- S. Alrubia, W. A. AlShehri, A. A. Radwan, N. Z. Alzoman and I. A. Darwish, Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro--5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation, BMC Chemistry 19 (2025) Article ID 27 (17 pages); https://doi.org/10.1186/s13065-024-01353-6
- I. A. Darwish and N. Z. Alzoman, Development of green and high throughput microplate reader-assisted universal microwell spectrophotometric assay for direct determination of tyrosine kinase inhibitors in their pharmaceutical formulations irrespective the diversity of their chemical structures, Molecules 28(10) (2023) Article ID 4049 (19 pages); https://doi.org/10.3390/molecules28104049
- International Conference for Harmonisation (ICH), Harmonised Guideline Q2 (R1) Validation of Analytical Procedures: Text and Methodology, Geneva, Dec 2023; Retrieved from https://database.ich.org/sites/default/files/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf; last access date March 18, 2025.
- International Conference for Harmonisation (ICH)/EMA, Harmonised Guideline (M10) Bioanalytical Method Validation and Study Sample Analysis-Step 4, Geneva, May 2022; https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf; last access date March 18, 2025.
- Waters, Wavelength cutoffs for common solvents; https://help.waters.com/help/en/product-support/alliance-is-system-support/715008450/6BCFA49.html; last access date March 18, 2025.
- A. Yusaf, M. Usman, A. Mansha, M. Siddiq, Z. Amjad, S. Irshad and H. Sultana, Self-organised surfactant assemblies as nanostructured dye carriers: a mixed micellar comparative approach for enhanced dye solubilisation, Int. J. Environ. Anal. Chem. 104 (2024) 2352–2363; https://doi.org/10.1080/03067319.2022.2060747
- A. A. Rana, A. Yusaf, S. Shahid, M. Usman, M. Ahmad, S. Aslam, S. A. Al-Hussain and M. E. A. Zaki, Unveiling the role of nonionic surfactants in enhancing cefotaxime drug solubility: A UV-visible spectroscopic investigation in single and mixed micellar formulations, Pharmaceuticals 16(12) (2023) Article ID 1663; https://doi.org/10.3390/ph16121663
- P. Patel, E. Howgate, P. Martin, D. J. Carlile, L. Aarons and D. Zhou, Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials, Br. J. Clin. Pharmacol. 84 (2018) 52–63; https://doi.org/10.1111/bcp.13404
- F. Shakeel, S. Alshehri, M. A. Ibrahim, M. Altamimi, N. Haq, E. M. Elzayat and G. A. Shazly, Solubilization and thermodynamic properties of simvastatin in various micellar solutions of different non-ionic surfactants: Computational modeling and solubilization capacity, PLoS ONE 16 (2021) e0249485; https://doi.org/10.1371/journal.pone.0249485
- ChemAxon. MarvinSketch Version 23.12., (Chemaxon Ltd., Budapest, Hungary); Retrieved from https://chemaxon.com/marvin; last access date March 18, 2025.
- D. Malyshev, R. Öberg, L. Landström, P. O. Andersson, T. Dahlberg and M. Andersson, pH-induced changes in Raman, UV-Vis absorbance, and fluorescence spectra of dipicolinic acid (DPA), Spectrochim. Acta A 271 (2022) Article ID 120869 (8 pages); https://doi.org/10.1016/j.saa.2022.120869
- S. Armenta, S. Garrigues and M. de la Guardia, Green analytical chemistry, TrAC Trends Anal. Chem. 27 (2008) 497–511; https://doi.org/10.1016/j.trac.2008.05.003
- A. Gałuszka, Z. M. Migaszewski, P. Konieczka and J. Namieśnik, Analytical Eco-Scale for assessing the greenness of analytical procedures, TrAC Trends Anal. Chem. 37 (2012) 61–72; https://doi.org/10.1016/j.trac.2012.03.013
- J. Płotka-Wasylka, A new tool for the evaluation of the analytical procedure: Green analytical procedure index, Talanta 181 (2018) 204–209; https://doi.org/10.1016/j.talanta.2018.01.013
- F. Pena-Pereira, W. Wojnowski and M. Tobiszewski, AGREE – Analytical GREEnness Metric approach and software, Anal. Chem. 92 (2020) 10076–10082; https://doi.org/10.1021/acs.anal-chem.0c01887